TSXV:RX

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

BioSyent Inc., a specialty pharmaceutical company, through its subsidiaries, sources, acquires or in-licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. More Details


Snowflake Analysis

Flawless balance sheet and fair value.

Share Price & News

How has BioSyent's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: RX is less volatile than 75% of Canadian stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: RX's weekly volatility (5%) has been stable over the past year.


Market Performance


7 Day Return

-0.7%

RX

9.2%

CA Pharmaceuticals

2.8%

CA Market


1 Year Return

8.5%

RX

14.8%

CA Pharmaceuticals

-0.3%

CA Market

Return vs Industry: RX underperformed the Canadian Pharmaceuticals industry which returned 13.1% over the past year.

Return vs Market: RX exceeded the Canadian Market which returned -0.5% over the past year.


Shareholder returns

RXIndustryMarket
7 Day-0.7%9.2%2.8%
30 Day0.7%30.1%10.0%
90 Day3.7%29.9%5.7%
1 Year8.5%8.5%14.8%14.8%3.3%-0.3%
3 Year-31.2%-31.2%-31.8%-32.9%12.2%1.3%
5 Year-0.7%-0.7%268.2%265.3%49.1%26.2%

Long-Term Price Volatility Vs. Market

How volatile is BioSyent's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is BioSyent undervalued compared to its fair value and its price relative to the market?

25.5%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: RX (CA$7.05) is trading below our estimate of fair value (CA$9.47)

Significantly Below Fair Value: RX is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: RX is good value based on its PE Ratio (19.4x) compared to the CA Pharmaceuticals industry average (23x).

PE vs Market: RX is poor value based on its PE Ratio (19.4x) compared to the Canadian market (15.3x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate RX's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: RX is overvalued based on its PB Ratio (3.6x) compared to the CA Pharmaceuticals industry average (1.5x).


Next Steps

Future Growth

How is BioSyent forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

14.5%

Forecasted annual revenue growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if RX's forecast earnings growth is above the savings rate (1.7%).

Earnings vs Market: Insufficient data to determine if RX's earnings are forecast to grow faster than the Canadian market

High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: RX's revenue (14.5% per year) is forecast to grow faster than the Canadian market (6.1% per year).

High Growth Revenue: RX's revenue (14.5% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if RX's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has BioSyent performed over the past 5 years?

6.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: RX has high quality earnings.

Growing Profit Margin: RX's current net profit margins (21.5%) are lower than last year (22.2%).


Past Earnings Growth Analysis

Earnings Trend: RX's earnings have grown by 6.1% per year over the past 5 years.

Accelerating Growth: RX's earnings growth over the past year (5.6%) is below its 5-year average (6.1% per year).

Earnings vs Industry: RX earnings growth over the past year (5.6%) exceeded the Pharmaceuticals industry -45%.


Return on Equity

High ROE: RX's Return on Equity (19.4%) is considered low.


Next Steps

Financial Health

How is BioSyent's financial position?


Financial Position Analysis

Short Term Liabilities: RX's short term assets (CA$26.6M) exceed its short term liabilities (CA$3.7M).

Long Term Liabilities: RX's short term assets (CA$26.6M) exceed its long term liabilities (CA$1.7M).


Debt to Equity History and Analysis

Debt Level: RX is debt free.

Reducing Debt: RX had no debt 5 years ago.

Debt Coverage: RX has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: RX has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Next Steps

Dividend

What is BioSyent current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate RX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate RX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if RX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if RX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of RX's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.


Next Steps

  • Explore strong dividend paying companies in the Pharmaceuticals & Biotech industry.

Management

How experienced are the management team and are they aligned to shareholders interests?

2.2yrs

Average management tenure


CEO

René Goehrum

21.5yrs

Tenure

CA$496,865

Compensation

Mr. René C. Goehrum has been the Chairman of BioSyent Inc. since June 1999 and its Chief Executive Officer since May 1999 and also its President since June 2006. Mr. Goehrum served as the President and ser...


CEO Compensation Analysis

Compensation vs Market: René's total compensation ($USD381.72K) is above average for companies of similar size in the Canadian market ($USD166.12K).

Compensation vs Earnings: René's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
René Goehrum
Chairman21.5yrsCA$496.87k7.26%
CA$ 6.7m
Robert March
VP of Finance & CFO2.17yrsCA$260.94k0.22%
CA$ 204.9k
Joost van der Mark
Vice President of Corporate Development2.17yrsCA$244.11k0.23%
CA$ 210.3k
Neelu Atwal
Director of Human Resources1.83yrsno data0.067%
CA$ 61.5k
Alfred D'Souza
2.17yrsCA$206.51kno data

2.2yrs

Average Tenure

Experienced Management: RX's management team is considered experienced (2.2 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
René Goehrum
Chairman21.5yrsCA$496.87k7.26%
CA$ 6.7m
Joseph Arcuri
Independent Director2.5yrsCA$29.90k0.80%
CA$ 731.1k
Peter Lockhard
Lead Independent Director2.83yrsCA$29.90k1.28%
CA$ 1.2m
Larry Andrews
Independent Director2.83yrsCA$27.60k0.080%
CA$ 73.7k
Sara Elford
Independent Director2.83yrsCA$27.60k0.11%
CA$ 100.8k
Stephen Wilton
Independent Director6.83yrsCA$27.60k0.011%
CA$ 10.1k

2.8yrs

Average Tenure

Experienced Board: RX's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

BioSyent Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: BioSyent Inc.
  • Ticker: RX
  • Exchange: TSXV
  • Founded:
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: CA$91.581m
  • Shares outstanding: 12.81m
  • Website: https://www.biosyent.com

Location

  • BioSyent Inc.
  • 2476 Argentia Road
  • Suite 402
  • Mississauga
  • Ontario
  • L5N 6M1
  • Canada

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
RXTSXV (TSX Venture Exchange)YesCommon SharesCACADSep 1988
BIOY.FOTCPK (Pink Sheets LLC)YesCommon SharesUSUSDSep 1988

Biography

BioSyent Inc., a specialty pharmaceutical company, through its subsidiaries, sources, acquires or in-licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/11/27 00:21
End of Day Share Price2020/11/26 00:00
Earnings2020/09/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.